Hematologists’ awareness of venous thromboembolism in multiple myeloma: a national survey in China

References

• Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009;27(29):1–10. doi:10.1200/JCO.2009.22.8197.
   PubMed Web of Science ®Google Scholar
• Schoen MW, Carson KR, Luo S, et al. Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost. 2020;4(7):1203–1210. doi:10.1002/rth2.12411.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Rajkumar SV, San Miguel JF, et al. International myeloma working group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014;32(6):587–600. doi:10.1200/JCO.2013.48.7934.
   PubMed Web of Science ®Google Scholar
• Swan D, Rocci A, Bradbury C, et al. Venous thromboembolism in multiple myeloma – choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol. 2018;183(4):538–556. doi:10.1111/bjh.15684.
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink L, Zhan F, et al. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk. 2011;11(2):228–236. doi:10.1016/j.clml.2011.03.006.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634. doi:10.1056/NEJMoa1516282.
   PubMed Web of Science ®Google Scholar
• Piedra K, Peterson T, Tan C, et al. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. Br J Haematol. 2022;196(1):105–109. doi:10.1111/bjh.17772.
   PubMed Web of Science ®Google Scholar
• Sanfilippo KM, Luo S, Wang TF, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94(11):1176–1184. doi:10.1002/ajh.25603.
   PubMed Web of Science ®Google Scholar
• Li A, Wu Q, Luo S, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Canc Netw. 2019;17(7):840–847. doi:10.6004/jnccn.2018.7273.
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials. Blood. 2020;136(9):1091–1104. doi:10.1182/blood.2020005125.
   PubMed Web of Science ®Google Scholar
• Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers. 2020;12(1):191. doi:10.3390/cancers12010191.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Bin Riaz I, Malik SU, et al. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis. Cancer. 2020;126(8):1640–1650. doi:10.1002/cncr.32682.
   PubMed Web of Science ®Google Scholar
• Chew HK, Wun T, Harvey D, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458–464. doi:10.1001/archinte.166.4.458.
   PubMed Web of Science ®Google Scholar
• Yang B, Liu C, Lin Z, et al. Nursing management of treatment-related venous thromboembolism in patients with multiple myeloma. Front Med. 2023;10:1153694. doi:10.3389/fmed.2023.1153694.
   Google Scholar
• Zheng W, Wei G, Ye X, et al. Bortezomib in combination with dexamethasone and subsequent thalidomide for newly-diagnosed multiple myeloma: a Chinese experience. Leuk Res. 2009;33(12):1615–1618. doi:10.1016/j.leukres.2009.04.006.
   PubMed Web of Science ®Google Scholar
• Guo H, Zhou X, Jiang Y, et al. Bortezomib plus intermediate-dose dexamethasone and thalidomide in elderly untreated patients with multiple myeloma: a Chinese experience. Am J Hematol. 2010;85(7):499–501. doi:10.1002/ajh.21734.
   PubMed Web of Science ®Google Scholar
• Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969–977. doi:10.1056/NEJMoa041533.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94(4):750–759. doi:10.1160/TH05-06-0385.
   PubMed Web of Science ®Google Scholar
• Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005;51(2–3):70–78. doi:10.1016/j.disamonth.2005.02.003.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907. doi:10.1182/blood-2007-10-116327.
   PubMed Web of Science ®Google Scholar
• Callander NS, Baljevic M, Adekola K, et al. NCCN guidelines(R) Insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8–19. doi:10.6004/jnccn.2022.0002.
   PubMed Web of Science ®Google Scholar
• Zangari M, Siegel E, Barlogie B, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100(4):1168–1171. doi:10.1182/blood-2002-01-0335.
   PubMed Web of Science ®Google Scholar
• Baz R, Li L, Kottke-Marchant K, et al. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clin Proc. 2005;80(12):1568–1574. doi:10.4065/80.12.1568.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152. doi:10.1056/NEJMoa1411321.
   PubMed Web of Science ®Google Scholar
• Griffin PT, Ho VQ, Fulp W, et al. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 2015;121(20):3622–3630. doi:10.1002/cncr.29533.
   PubMed Web of Science ®Google Scholar
• Wang J, Kim Y. Risk of thromboembolism in patients with multiple myeloma treated with daratumumab: a systemic review and meta-analysis. Int J Hematol. 2020;112(5):650–657. doi:10.1007/s12185-020-02954-2.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Larocca A, Carpenedo M, et al. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica. 2022;107(11):2536–2547. doi:10.3324/haematol.2022.280893.
   PubMed Web of Science ®Google Scholar
• Sanfilippo KM, Carson KR, Wang TF, et al. Evaluation of the khorana score for prediction of venous thromboembolism in patients with multiple myeloma. Res Pract Thromb Haemost. 2022;6(1):e12634. doi:10.1002/rth2.12634.
   PubMed Web of Science ®Google Scholar
• Koh Y, Bang SM, Lee JH, et al. Low incidence of clinically apparent thromboembolism in korean patients with multiple myeloma treated with thalidomide. Ann Hematol. 2010;89(2):201–206. doi:10.1007/s00277-009-0807-6.
   PubMed Web of Science ®Google Scholar
• Raghupathy R, Ayyappan S, Prabhakar D, et al. Retrospective study of the incidence and patterns of arterial and venous thrombosis in Chinese versus African American patients with multiple myeloma. Br J Haematol. 2017;176(2):315–317. doi:10.1111/bjh.13942.
   PubMed Web of Science ®Google Scholar